Brief: Hikma Expands Licensing Agreement With Celltrion For Remsima Subcutaneous Formulation In MENA
07/02/2022 13:34
Feb 7 (Reuters) - Hikma Pharmaceuticals PLC:
* HIKMA - EXPANDS LICENSING AGREEMENT WITH CELLTRION FOR
REMSIMA
SUBCUTANEOUS FORMULATION IN MENA
Source text for Eikon: ID:
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares